Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License Application, or sBLA, for Dupixent to treat adults and pediatric ...
Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn ...
Dupixent may become the first targeted treatment for bullous pemphigoid in the U.S., pending FDA approval by June 2025. Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a ...
FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade Safety results in all LIBERTY-CUPID Phase 3 trials were generally consistent with ...
Paris and Tarrytown, N.Y. September 26, 2023. The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent ® ...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA ...
Regeneron Pharmaceuticals and Sanofi have won Food and Drug Administration priority review of their application seeking expanded approval of their blockbuster anti-inflammatory drug Dupixent for ...
Paris and Tarrytown, NY May 31, 2024. The US Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License ...
The FDA has approved Dupixent as the first new targeted therapy in over ten years for chronic spontaneous urticaria in patients aged 12 and older who remain symptomatic despite antihistamine treatment ...
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision ...
Sanofi stock is up 21.89% year-to-date. Its eight-day, 20-day, 50-day and even 200-day moving averages all point higher. The stock also completed a Golden Cross, where the 50-day moving average ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results